AKI Therapeutics A/S: Financial statements 2022
CVR: 37509736
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 0 and a net result of DKK -1,117,346 compared with DKK -1,523,621 the year before. Equity in the 2022 report amounted to DKK 2,455,280. The solvency ratio was 73.9%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -1,117,346
- Equity
- DKK 2,455,280
- Total Assets
- DKK 3,321,355
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 | 0 | -1.1M | 2.5M | - |
| 2021 | 0 | -12K | -1.5M | 3.6M | - |
| 2020 | - | -89K | 148K | 115K | - |
| 2019 | - | -127K | 28K | 52K | - |
| 2018 | - | -5K | -5K | 24K | - |
Official annual report
Keep an eye on AKI Therapeutics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
AKI Therapeutics A/S has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -1,523,621.
As of May 31, 2022, Troels Ring has left the board of directors of AKI Therapeutics A/S.
On May 31, 2022, the company changed its name from AKI Therapeutics ApS to AKI Therapeutics A/S.
About AKI Therapeutics A/S
AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.
